Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Vidal Group

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

- PMLiVE

M3 appoints Simon Walker as director of education

In his new role he will lead the company's educational strategy

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

- PMLiVE

Allergan adds Zeltiq to M&A roster in $2.48n deal

Expands aesthetic pharma business with “best-in-class” body contouring system

- PMLiVE

Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

- PMLiVE

Stada confirms Cinven as one of two takeover bidders

Private equity group offers €3.6bn for the generics and over-the-counter medicines manufacturer

- PMLiVE

Cello Health expands with Defined Health acquisition

Builds US presence with biotech-focused strategy specialist

- PMLiVE

A digital strategy in a digital world

The digital communication age has dawned, and whatever profession we’re in, we’re dependent upon technology. Data published by Ofcom in 2016 illustrates how the UK population spends more time using...

- PMLiVE

Celgene pays $300m upfront for immunology start-up Delinia

Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

- PMLiVE

J&J agrees $30bn deal to acquire Actelion

Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

- PMLiVE

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links